BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33159829)

  • 1. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
    Shiota M; Terada N; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Mizowaki T; Kamoto T; Kojima T; Kitamura H; Sugimoto M; Nishiyama H; Eto M;
    Cancer Sci; 2021 Apr; 112(4):1524-1533. PubMed ID: 33159829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.
    Shiota M; Terada N; Kitamura H; Kojima T; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Sugimoto M; Mizowaki T; Kamoto T; Nishiyama H; Eto M;
    Cancer Sci; 2021 Sep; 112(9):3616-3626. PubMed ID: 34145921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With
    Kobayashi T; Namitome R; Hirata YU; Shiota M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2019 Jun; 39(6):3191-3195. PubMed ID: 31177166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
    Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
    World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
    Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
    Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
    Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
    Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
    Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score ≥8.
    Morozumi K; Mitsuzuka K; Narita S; Takahashi M; Kawamura S; Tochigi T; Arai Y; Hoshi S; Shimoda J; Ishidoya S; Okamoto T; Hatakeyama S; Sakurai T; Tsuchiya N; Ohyama C; Habuchi T; Ito A
    Int J Urol; 2022 Apr; 29(4):324-331. PubMed ID: 35042278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
    Nagumo Y; Onozawa M; Kojima T; Terada N; Shiota M; Mitsuzuka K; Yasumoto H; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Saito T; Yokomizo A; Kohei N; Tabata KI; Takahashi A; Sugimoto M; Kitamura H; Kamoto T; Nishiyama H;
    Int J Urol; 2022 May; 29(5):398-405. PubMed ID: 35080069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy.
    Shiota M; Yokomizo A; Takeuchi A; Imada K; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):495-503. PubMed ID: 25227457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of the prognostic nutritional index in patients with metastatic hormone-sensitive prostate cancer: A retrospective, multicenter, cohort study.
    Yamada Y; Sakamoto S; Sato K; Saito S; Kanesaka M; Rii J; Kurokawa K; Tachiwaki D; Fukui Y; Shibata H; Goto Y; Sazuka T; Imamura Y; Nakatsu H; Ichikawa T
    Prostate; 2023 Dec; 83(16):1610-1618. PubMed ID: 37690087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
    Ebbinge M; Berglund A; Varenhorst E; Hedlund PO; Sandblom G;
    BJU Int; 2018 Oct; 122(4):583-591. PubMed ID: 29611275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with
    Turner PG; Jain S; Cole A; Grey A; Mitchell D; Prise KM; Hounsell AR; McGarry CK; Biggart S; O'Sullivan JM
    Clin Cancer Res; 2021 Aug; 27(16):4549-4556. PubMed ID: 34187853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
    Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
    Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
    Nagata Y; Matsukawa T; Tomisaki I; Fujimoto N
    Anticancer Res; 2022 Feb; 42(2):1107-1114. PubMed ID: 35093913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
    Clarke NW; Ali A; Ingleby FC; Hoyle A; Amos CL; Attard G; Brawley CD; Calvert J; Chowdhury S; Cook A; Cross W; Dearnaley DP; Douis H; Gilbert D; Gillessen S; Jones RJ; Langley RE; MacNair A; Malik Z; Mason MD; Matheson D; Millman R; Parker CC; Ritchie AWS; Rush H; Russell JM; Brown J; Beesley S; Birtle A; Capaldi L; Gale J; Gibbs S; Lydon A; Nikapota A; Omlin A; O'Sullivan JM; Parikh O; Protheroe A; Rudman S; Srihari NN; Simms M; Tanguay JS; Tolan S; Wagstaff J; Wallace J; Wylie J; Zarkar A; Sydes MR; Parmar MKB; James ND
    Ann Oncol; 2019 Dec; 30(12):1992-2003. PubMed ID: 31560068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a novel risk model in newly diagnosed
    Zhang Y; Wang J; Ding L; Zheng Y; Wu C; Wang K; Xia W; Ge P
    PeerJ; 2023; 11():e14615. PubMed ID: 36650836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
    Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
    Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.